Virpax Pharmaceuticals (VRPX) Competitors $0.02 0.00 (0.00%) As of 12:30 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRPX vs. PBLA, NKGN, SMFL, SCPS, VAXX, TRVN, ARDS, NAVB, EVLO, and GNCAQShould you be buying Virpax Pharmaceuticals stock or one of its competitors? The main competitors of Virpax Pharmaceuticals include Panbela Therapeutics (PBLA), NKGen Biotech (NKGN), Smart for Life (SMFL), Scopus BioPharma (SCPS), Vaxxinity (VAXX), Trevena (TRVN), Aridis Pharmaceuticals (ARDS), Navidea Biopharmaceuticals (NAVB), Evelo Biosciences (EVLO), and Genocea Biosciences (GNCAQ). These companies are all part of the "pharmaceutical products" industry. Virpax Pharmaceuticals vs. Its Competitors Panbela Therapeutics NKGen Biotech Smart for Life Scopus BioPharma Vaxxinity Trevena Aridis Pharmaceuticals Navidea Biopharmaceuticals Evelo Biosciences Genocea Biosciences Panbela Therapeutics (NASDAQ:PBLA) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation. Do insiders and institutionals have more ownership in PBLA or VRPX? 4.4% of Panbela Therapeutics shares are owned by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 0.0% of Panbela Therapeutics shares are owned by company insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor PBLA or VRPX? In the previous week, Panbela Therapeutics' average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score. Company Overall Sentiment Panbela Therapeutics Neutral Virpax Pharmaceuticals Neutral Is PBLA or VRPX more profitable? Panbela Therapeutics' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Panbela TherapeuticsN/A N/A -302.61% Virpax Pharmaceuticals N/A -1,554.34%-338.29% Which has stronger earnings & valuation, PBLA or VRPX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPanbela TherapeuticsN/AN/A-$25.26M-$71.130.00Virpax PharmaceuticalsN/AN/A-$15.19MN/AN/A Which has more volatility & risk, PBLA or VRPX? Panbela Therapeutics has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Comparatively, Virpax Pharmaceuticals has a beta of 1.96, indicating that its stock price is 96% more volatile than the S&P 500. SummaryVirpax Pharmaceuticals beats Panbela Therapeutics on 4 of the 6 factors compared between the two stocks. Get Virpax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart VRPX vs. The Competition Export to ExcelMetricVirpax PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$26K$1.03B$6.02B$10.45BDividend YieldN/A4.84%5.73%4.82%P/E RatioN/A1.2885.1227.23Price / SalesN/A30.15589.70134.52Price / CashN/A17.6425.7730.18Price / Book0.017.7012.676.76Net Income-$15.19M-$7.59M$3.32B$276.50M7 Day PerformanceN/A10.61%0.49%0.85%1 Month PerformanceN/A22.16%9.41%8.16%1 Year PerformanceN/A-10.96%79.11%43.62% Virpax Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRPXVirpax Pharmaceuticals0.053 of 5 stars$0.02flatN/A-99.8%$26KN/A0.007Gap UpPBLAPanbela Therapeutics0.0923 of 5 stars$0.01+0.9%N/A-96.9%$54KN/A0.006NKGNNKGen Biotech0.1394 of 5 stars$0.00+150.0%N/A-96.4%$22KN/A0.00N/AGap UpSMFLSmart for LifeN/A$0.00+25.0%N/A-93.7%$18K$11.11M0.00110Gap DownSCPSScopus BioPharmaN/A$0.00flatN/AN/A$13KN/A0.009Gap UpVAXXVaxxinityN/A$0.00-99.0%N/A-97.5%$13KN/A0.0090Gap UpTRVNTrevena1.634 of 5 stars$0.01flat$5.00+41,566.7%-99.4%$12K$443K0.0040ARDSAridis PharmaceuticalsN/A$0.00flatN/AN/A$11KN/A0.0030High Trading VolumeNAVBNavidea BiopharmaceuticalsN/AN/AN/AN/A$10K$8.13K0.0010EVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070 Related Companies and Tools Related Companies PBLA Alternatives NKGN Alternatives SMFL Alternatives SCPS Alternatives VAXX Alternatives TRVN Alternatives ARDS Alternatives NAVB Alternatives EVLO Alternatives GNCAQ Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRPX) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredWhy Wall Street is piling into the “Debasement Trade”Wall Street is piling into what insiders are calling the “Debasement Trade” — and according to former Goldman ...Stansberry Research | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virpax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virpax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
